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Summary
Inhibition of ERK-MAPK signaling by expression of dominant-negativeMEK1 in the tumor vasculature suppresses angiogen-
esis and tumor growth. In an organotypic tissue culture angiogenesis assay, ERK-MAPK inhibition during the migratory
phase results in loss of bipolarity, detachment, and cell death of isolated endothelial cells and retraction of sprouting tu-
bules. These effects are the consequence of upregulated Rho-kinase signaling. Transient inhibition of Rho-kinase rescues
the effects of ERK-MAPK inhibition in vitro and in vivo, promotes sprouting, and increases vessel length in tumors. We pro-
pose a regulatory role of Rho-kinase by ERK-MAPK during angiogenesis that acts through the control of actomyosin con-
tractility. Our data delineate a mechanism by which ERK-MAPK promotes endothelial cell survival and sprouting by down-
regulating Rho-kinase signaling.Introduction
The tumor vasculature is an important target in cancer therapy,
as the growth andmetastasis of tumors depends on their vascu-
lar network (Folkman, 1990; Zetter, 1998). Understanding the
signaling pathways that control angiogenesis will aid identifi-
cation of therapeutic targets and the design of effective antian-
giogenic therapies. Tumors employ diverse mechanisms for
vessel formation, including sprouting from existing blood ves-
sels (Ergun et al., 2001), de novo recruitment of endothelial pre-
cursors (Lyden et al., 2001), vessel remodeling (Patan et al.,
1996), and cooption (Holash et al., 1999). Endothelial cell behav-
ior during these processes is regulated by diverse signals from
growth factors, cytokines, and the extracellular matrix (Ferrara,
2002). Studies show that such signals converge on common
signaling pathways that control cell proliferation, survival, migra-
tion, and morphogenesis (Liotta and Kohn, 2001). The compo-
nents of these signaling pathways therefore constitute potential
targets for antiangiogenic therapy.
It has been suggested that the RAS-RAF-MEK-ERK signaling
module is involved in tumor angiogenesis (Mukhopadhyay et al.,
1998), and there is evidence in endothelial cells that MAPK-ERK
signaling plays a central role during angiogenesis.Mek1 knock-
out mice have defective angiogenesis in the placenta and are
embryonic lethal (Giroux et al., 1999). Dominant-negative RafCANCER CELL 9, 33–44, JANUARY 2006 ª2006 ELSEVIER INC. DOI 10.1targeted to the neovasculature of tumors induces endothelial
apoptosis and inhibits tumor growth (Hood et al., 2002). Inhibi-
tion of ERK-MAPK signaling suppresses the formation of new
blood vessels in response to growth factor stimulation in the
chorioallantoic membrane in vivo (Eliceiri et al., 1998). ERK-
MAPK signaling has been implicated in endothelial cell prolifer-
ation (Meadows et al., 2001), VEGF-mediated survival (Berra
et al., 2000; Gupta et al., 1999), and protection against recep-
tor-mediated apoptosis (Alavi et al., 2003). Another way ERK-
MAPK signaling is thought to stimulate angiogenesis is by pro-
moting endothelial cell motility (Eliceiri et al., 1998). Although
the mechanism of activation of MAPK-ERK in endothelial cells
by growth factors and integrins (Eliceiri et al., 1998) and the
differential regulation of Raf-1 by different stimuli (Hood et al.,
2003) have been characterized, it is not clear how ERK-MAPK
signaling mediates its effects during tumor angiogenesis in
vivo. Moreover, the mechanism by which ERK-MAPK promotes
endothelial cell survival and influences motility are not under-
stood.
In addition to ERK-MAPK signaling, there is evidence that Rho
family GTPase signaling is involved in angiogenesis. Members
of this family are activated in response to growth factors and
cell-matrix adhesion and are key regulators of the actin cyto-
skeleton (Etienne-Manneville and Hall, 2002). Inhibition of Rho
family GTPases disrupts tube formation in three-dimensionalS I G N I F I C A N C E
Delineating signaling pathways in endothelial cells in their physiological context is likely to generate more effective antiangiogenic
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angiogenesis assay. We show that ERK-MAPK opposes Rho-kinase-dependent actomyosin contractility to promote endothelial cell
survival and vessel sprouting. While inhibition of ERK-MAPK in the tumor vasculature inhibits angiogenesis, inhibition of Rho-kinase pro-
motes sprouting and increases vessel length. Our data delineate a role for ERK-MAPK signaling during angiogenesis and demonstrate
that transiently inhibiting Rho-kinase may have a positive effect on tumor angiogenesis.016/j.ccr.2005.12.021 33
A R T I C L Ematrices in vitro (Cascone et al., 2003; Hoang et al., 2004). The
activity of the prototypical member of the family, Rho, has been
shown to be necessary for VEGF-driven angiogenesis in the
chorioallantoic membrane, and the VEGF-mediated organi-
zation of endothelial cells into vessels in a skin angiogenesis
model in vivo (Hoang et al., 2004). The serine/threonine kinases
ROCKI/II (also referred to as ROKb/a or Rho-kinase) are effec-
tors of RhoA and RhoC. They control actomyosin contractility
by leading to the phosphorylation of the regulatory myosin light
chain II (MLC2) either directly or via inhibiting the myosin binding
subunit (MYPT1) of myosin light chain phosphatase (MLCP)
(Riento and Ridley, 2003). They also regulate actin assembly
by activating LIM kinase (Riento and Ridley, 2003). The control
of actomyosin contractility and actin assembly are thought to
be key to the way Rho-kinase regulates cell migration, with a
net positive or negative effect of Rho-kinase inhibition on migra-
tion depending upon the cell type and conditions (Riento and
Ridley, 2003). In endothelial cells, Rho-kinase may havemultiple
functions during angiogenesis. Inhibiting Rho-kinase inhibits en-
dothelial permeability, and it has been suggested that this is by
disrupting endothelial cell tight junctions (Wojciak-Stothard and
Ridley, 2002). In different assays of endothelial cell function in
culture, Rho-kinase inhibition has been shown to disrupt vacu-
ole formation and increase cellular protrusions, resulting in dis-
ruption of cord formation (Somlyo et al., 2003). These studies
suggest that the regulation of Rho signaling plays an important
role during angiogenesis.
Previously, it has been shown that pharmacological inhibition
of ERK-MAPK activation compromises tumor growth in experi-
mental animals without leading to toxicity (Sebolt-Leopold et al.,
1999). Given the observations that ERK-MAPK signaling plays
a role in angiogenesis (Eliceiri et al., 1998; Giroux et al., 1999;
Gupta et al., 1999; Berra et al., 2000; Meadows et al., 2001;
Hood et al., 2002), we sought to investigate whether selective in-
hibition of ERK-MAPK activation in the vascular compartment of
tumors would inhibit tumor growth. We show that selective ex-
pression of dominant-negative MEK1 in the tumor vasculature
results in reduced vascularization and tumor growth. To delin-
eate the mechanism, we used an organotypic angiogenesis as-
say, in which vessel formation results from interaction of endo-
thelial cells with fibroblasts (Bishop et al., 1999). Recently, it has
been shown that such cocultures generate stable and long-
lasting vessels when implanted in mice (Koike et al., 2004). By
following endothelial cell migration and sprouting in real time
by time-lapse microscopy, we show that ERK-MAPK signaling
promotes endothelial cell survival and vessel sprouting by
downregulating Rho-kinase activity. Rescue of the effects of
ERK-MAPK inhibition by transiently inhibiting Rho-kinase in
the tumor angiogenesis model confirms that this mechanism
operates in tumors. Our data suggest that the balance between
ERK-MAPK and Rho-kinase signaling is a key determinant of
vascular morphogenesis in vivo and demonstrate that inhibition
of ERK-MAPK in the vascular compartment of tumors alone can
compromise tumor growth.
Results
ERK-MAPK signaling in the vascular compartment of
tumors is necessary for angiogenesis and tumor growth
To block activation of the MAPKs ERK1/2 in blood vessels,
we selectively expressed dominant-negative MEK1 (MEK1A;34Cowley et al., 1994) in the vascular compartment of human
tumor cell lines growing as xenografts in nude mice. Selective
transgene expression in the vascular compartment of tumors
is achieved by coinjection of tumor cells with irradiated eco-
tropic retrovirus producers (Mavria and Porter, 2001). In this
experimental setting, the ecotropic retrovirus infects murine
endothelial cells and some tumor-associated fibroblasts in the
host-derived stroma but not the human cancer cells (Mavria
and Porter, 2001 and Figure S1A in the Supplemental Data avail-
able with this article online). The irradiated virus producers dis-
appear from the tumor mass within 2 weeks of tumor growth
(Mavria and Porter, 2001). The BE colorectal cancer cell line
was chosen because it forms well-vascularized tumors in mice
(G.M., unpublished data). BE tumors with MEK1A transduction
in the vascular compartment resulting from the coinjection of
tumor cells with MEK1A virus producers grew at a slower rate
compared to tumorswith control EGFP transduction for 5 weeks
after the tumors appeared (Figure 1A), whereas at later time as
expected tumor growth resumed (data not shown). Coinjection
of tumor cells with producer cells making an ecotropic retrovirus
encoding a constitutively activated version of MEK1 (MEK1EE;
Cowley et al., 1994) had little effect on the growth of these
fast-growing tumors. In contrast, when the slow-growing breast
cancer cell line MDA-MB-361 was coinjected with producer
cells making the ecotropic MEK1EE virus, tumor growth was
considerably enhanced compared with controls (Figure 1A).
Therefore, manipulation of ERK1/2 signaling in the vascular
compartment modifies tumor growth.
To determinewhether the observed reduction in tumor growth
was associated with defective angiogenesis, tumors were dis-
sected out for analysis of their blood vessels by staining for the
endothelial cell marker CD31. Representative pictures of BE tu-
mors with dominant-negativeMEK1 transduction in the vascular
compartment are shown in Figure 1B.We quantitated the overall
CD31-stained area as a total measure of vasculature. Vessel
length, the number of branching points, and vessels with open
lumenswere used asmeasures of vesselmorphogenesis. Quan-
titation revealed 25% reduction in vessel area, 71% reduction
in the number of vessels with open lumens, and 42% reduction
in the number of branching points of MEK1A tumors compared
to control (Figures 1C–1E). In addition, there was a 49% de-
crease in the number of longer vessels (Table 1). Consistently,
MDA-MB-361 tumors expressing constitutively active MEK1
(MEK1EE) in the vascular compartment had larger vessels with
open lumens compared to controls (Figure S1C). Altogether,
these results show that ERK-MAPK signaling is necessary for tu-
mor angiogenesis and that inhibition of ERK-MAPK signaling in
the vascular compartment alone can compromise tumor growth.
Distinct stages during tube formation
in endothelial-fibroblast cocultures
In order to investigate the mechanism of inhibition of angiogen-
esis in response to inhibition of ERK-MAPK signaling, we chose
a tissue culture organotypic angiogenesis assay (TCS Angiokit)
in which tubule formation results from the interaction between
human umbilical vein endothelial cells (HUVECs) and human
dermal fibroblasts (HDFs). Coculture of these cell types gives
rise to tubules with lumens embedded in naturally produced
extracellular matrix (Bishop et al., 1999) that show a better re-
semblance to capillaries in vivo than tubes formed by monocul-
tures of endothelial cells in matrigel (Donovan et al., 2001).CANCER CELL JANUARY 2006
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genic factors bFGF and VEGF (Ferrara, 2002). FGF is supplied
in the culture medium (TCS CellWorks), whereas VEGF is pro-
duced by the coculture system (see Table S1). Both antibodies
to VEGF and VEGF antisense reagents have been shown to in-
hibit tube formation in this system (Table S2). The coculture as-
say is sensitive to a large number of well-established inhibitors
of angiogenesis, including thrombospondin derivatives, endo-
statin, RGD peptide, and MMP inhibitors (Table S2). In this
Figure 1. Expression of dominant-negative MEK1 in the vascular compart-
ment of tumors suppresses angiogenesis and tumor growth
A: Tumor growth analysis. Tumors with MEK1A (dominant-negative MEK1),
MEK1EE (constitutively active MEK1), or control (EGFP) retroviral transduction
in the vascular compartment were set up as described in Experimental Pro-
cedures (left panel, BE colon carcinoma; right panel, MDA-MB-361 breast
carcinoma). Graphs indicate the mean tumor growth rates 6 SD. x axis:
days after the appearance of tumors. Shown on the BE control growth curve
are the numbers of animals with tumor size < 1500 mm3. All tumors with
MEK1EE expression in the vasculature reached maximum diameter by day
15. B: Tumor vessel appearance. BE tumors were analyzed when they
reached approximately 0.6 cm diameter; cryosections were examined by
immunofluorescence for CD31 expression. Two sections typical of the differ-
ence between tumors with MEK1A and control retroviral transduction are
shown. Scale bar, 100 mm. The fractional area covered by CD31+ features
(C), the number of vessels with open lumens (D), and the number of branch-
ing points (E) are represented as mean6 SD (n = 4 tumors). Counts for each
tumor were from eight sections, representing four different levels. For each
section, the microscopic field (320) showing the greatest level of CD31
staining was counted.CANCER CELL JANUARY 2006study, wemodified the coculture assay by using HUVECs stably
expressing EGFP to permit monitoring tubule formation by time-
lapse microscopy. Real-time tracking after initiation of the co-
culture revealed three distinct stages during the assay. In the
early stage of the coculture, endothelial cells appeared flat-
tened, had multiple protrusions, and exhibited random cell mo-
tility (Figure 2 and data not shown). During this stage, endothelial
cells often formed small islands, and there was high endothelial
cell proliferation (data not shown). This early stage was followed
by a migratory phase approximately 1 week after initiation of the
coculture (Figure 2). During this phase, endothelial cells became
bipolar, migrated in a directional manner, and assembled into
tubules (Figure 2 andMovie S1). In addition, there was sprouting
from islands of endothelial cells that had formed during the pro-
liferative phase and from early tubules, and there was little or no
proliferation (Movie S1). After 2 weeks in coculture, the tubules
were established, there was further thickening, and some elon-
gation could be observed (Figure 2 and data not shown). At this
stage, there was expression of VE-cadherin at endothelial cell
junctions (data not shown).
ERK-MAPK signaling in endothelial cells during the
migratory phase is necessary for tube formation
in endothelial-fibroblast cocultures
To investigate the role of ERK1/2 signaling in endothelial cells
during tube formation, we inhibited ERK1/2 activation during
the migratory phase of the endothelial-fibroblast coculture
1 week after its initiation, using the pharmacological inhibitor
PD184352 at concentrations that inhibit activation of ERK1/2
but not ERK5 (Mody et al., 2001). Treatment of the cocultures
for 48 hr during this phase had a marked antiangiogenic effect
(Figure 3A). EC proliferation at earlier stages was unaffected
by inhibition of ERK-MAPK signaling, while treatment of cocul-
tures once the tubes had already established had little effect
(data not shown), arguing that ERK1/2 signaling is necessary
during themigratory phase. To determine whether there was ap-
optosis in response to inhibition of ERK-MAPK signaling, we
stained the cocultures with TUNEL (Figure 3B). We observed
that it was single endothelial cells that were TUNEL positive after
PD184352 treatment as opposed to endothelial cells that had
assembled into tubules. However, cell rounding was noticeable
at the tips of those tubules (Figure 3B). Using time-lapsemicros-
copy, we found that cell death occurred over a period of 12–
18 hr of inhibitor treatment (Movie S2). To find out whether this
effect was on endothelial cell signaling, ERK1/2 was inhibited
specifically in endothelial cells by means of expressing
Table 1. Vessel length analysis
Vessel
length per
field (a.u.)
Frequency (%) of
vessel length (a.u.)
Median
(a.u.)0–3 3–5 >5
Control 141.6 (69.3) 72.6 14.5 12.8 1.8
MEK1A 104.1 (611.1)* 80.8 12.4 6.5 1.5
MEK1A + Y27632 134.7 (611.9)** 76.6 11.5 11.9 1.6
Y27632 132.1 (611.9) 66.5 15.5 17.9 2.0
Vessel length is the average value of the sum of individual vessel lengths in
each of 32 fields representing the area of highest vessel density of a section.
Sections were from four tumors per group, with eight sections representing
four different levels in a tumor. *p < 0.002 with respect to control (n = 4);
**p < 0.02 with respect to DN MEK (n = 4). a.u., arbitrary units.35
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pression of MEK1A in HUVECs resulted in inhibition of angio-
genesis in coculture (Figure 3C). Stable expression of MEK1A
in HUVECs had no effect when the cells were cultured alone.
In an alternative approach to inhibit ERK1/2 activation specifi-
cally in endothelial cells, HUVECs were transfected with siRNAs
against Raf-1 and B-Raf and seeded onto a confluent layer of fi-
broblasts. When seeded on confluent fibroblasts, HUVECs rap-
idly enter the migratory phase with little or no proliferation and
form tubes (see Movie S4). Figure 3D shows that there was re-
duced tube formation when ERK1/2 activation was inhibited
with Raf siRNAs. We found that it was necessary to silence ex-
pression of both Raf-1 and B-Raf to downregulate ERK phos-
phorylation (Figure S2), arguing that both these kinases contrib-
ute to the activation of ERK1/2 in HUVECs (data not shown).
These experiments show that ERK1/2 signaling in endothelial
cells during the migratory phase is required for endothelial cell
survival. Since both Raf-1 and B-Raf were necessary to control
ERK-dependent survival during the migratory phase in this
study, it is possible that the documented ERK-independent
role of Raf-1 in endothelial cell survival (Alavi et al., 2003) is
more relevant during the proliferative stage.
ERK-MAPK signaling is necessary for endothelial
cell bipolarity, attachment, and survival during the
migratory phase
During migration and vessel formation, endothelial cells adopt
bipolar and elongated cell morphology (Figure 2). While follow-
ing the survival of isolated endothelial cells in response to
PD184352 treatment, time-lapse microscopy revealed distinct
Figure 2. Three stages during angiogenesis in coculture of endothelial cells
with fibroblasts
HUVEC-EGFP were cocultured with human dermal fibroblasts (HDFs), and
tube formation was followed by time-lapse microscopy. Video stills are
shown at 12 hr intervals over a 48 hr period for each stage. Three stages of
endothelial behavior are distinguishable: ‘‘early,’’ where endothelial cells
proliferate and have random motility (images are shown at days 4–6 after
initiation of a coculture); ‘‘migratory,’’ where endothelial cells adopt a bi-
polar morphology, migrate in a directional manner, assemble into vessels,
and sprout (images are from a day 7–9 coculture); and ‘‘established,’’
where vessels become thicker with some elongation (images are from
days 14–16 of a coculture). Scale bar, 50 mm.36changes in endothelial cell morphology as shown by loss of bi-
polarity, preceding endothelial cell apoptosis (Movie S2). To
demonstrate this better, we seeded HUVECs stably expressing
MEK1A on confluent fibroblasts. There was loss of bipolarity of
HUVEC-MEK1A cells within 18 hr of seeding (Figure 4A). Within
24 hr, HUVEC-MEK1A had detached, while control HUVECs had
started aligning into tube-like structures. Movies of loss of bipo-
larity, detachment, and cell death can be seen in Movies S3 and
S4. A loss of bipolarity that was similar to that seen in HUVEC-
MEK1A was observed when HUVECs seeded on confluent
fibroblasts were treated with PD184352 or Raf siRNAs (Figures
4B and 4C, respectively) that led to detachment from the fibro-
blast layer and cell death, as revealed by time-lapsemicroscopy
(Figures 4B and 4D). These experiments suggest that endothe-
lial apoptosis in response to inhibition of ERK-MAPK signaling
results from changes in cell morphology leading to altered cell
adhesion and detachment from the extracellular matrix.
ERK-MAPK signaling is necessary for sprouting
by endothelial cells
The ablation of angiogenesis in response to inhibition of ERK1/2
signaling during the migratory phase in coculture (Figure 3A)
suggested that, in addition to isolated endothelial cells, inhibi-
tion of ERK1/2 signaling affected the tubules that had already
formed at this stage. In order to confirm this hypothesis and un-
derstand the mechanism underlying the response, we followed
sprouting tubules during PD184352 treatment by time-lapse mi-
croscopy. The movies revealed that sprouting tubules retracted
during PD184352 treatment, whereas control tubules continued
remodeling (Figure 5A). The retraction induced by PD184352
treatment was irreversible, as there was no recovery when the
inhibitor was washed out (Figure 3 and data not shown). To con-
firm that retraction was due to inhibition of ERK-MAPK signaling
in endothelial cells, we measured the number of sprouts in tu-
bules formed by HUVECs transfected with Raf siRNAs seeded
on confluent fibroblasts. Figure 5B shows that there was re-
duced number of sprouts per vessel when ERK1/2 activation
was inhibited in endothelial cells with the combination of Raf
siRNAs.
ERK-MAPK opposes Rho-kinase signaling during
vessel formation
The rounding of single cells and retraction of sprouting vessels
observed in response to inhibition of ERK-MAPK signaling sug-
gest that signaling pathways that control the morphology of en-
dothelial cells are deregulated. Signaling through Rho and Rho-
kinase has been implicated in cell retraction (Amano et al.,
1998). Previous studies have shown that inhibition of ERK-
MAPK signaling in cancer cells can lead to upregulation of
Rho-Rho-kinase signaling (Vial et al., 2003). As cocultures con-
tain a small proportion of endothelial cells (approximately 5% in
the migratory phase), the activation status of Rho-kinase signal-
ing in endothelial cells could not be determined by direct bio-
chemical analysis. Therefore, we looked by immunofluores-
cence for changes in the phosphorylation state of myosin light
chain 2, a target of Rho-kinase signaling involved in cell retrac-
tion (Amano et al., 1996, 1998). When control 1-week-old cocul-
tures were stained, some pMLC was detected that often local-
ized to the tips of vessels. Treatment of cocultures with
PD184352 significantly increased pMLC staining in endothelial
cells within 4 hr of treatment (Figure 6A, left panel). In theseCANCER CELL JANUARY 2006
A R T I C L EFigure 3. Inhibition of ERK-MAPK signaling in endothelial cells during the migratory phase results in abrogation of tube formation
A: HUVECs were cocultured with HDFs, and after 7 days the MEK inhibitor PD184352 (2 mM) was applied for 48 hr; the inhibitor was then removed and replaced
with fresh medium. Vessel formation was assessed by CD31 staining after a further 5 days. Inset: Western blot shows ERK1/2 phosphorylation in HUVECs treated
with PD184352 compared to control. Scale bar, 100 mm.
B: HUVECs were cocultured with HDFs, and after 7 days the MEK inhibitor PD184352 was applied for 18 hr. The cocultures were then fixed, HUVECs were visu-
alized by CD31 immunostaining, and apoptotic cells were detected by TUNEL. Scale bar, 50 mm. The rightmost panels are32 magnifications of the inset shown
in the middle panel. Open arrow shows apoptotic endothelial cells; closed arrow shows cell rounding at tip of vessel.
C: Vessel formation of HUVECs expressing dominant-negative MEK1 (MEK1A) compared to control HUVEC-EGFP was assessed by CD31 staining after 2 weeks
coculture with HDFs. Results shown are representative of three independent experiments using three different pools of HUVEC-MEK1A carried out in triplicates.
Tubule count is represented as6SD (n = 9 microscopic fields at34 magnification). Images show representative vessel formation after 2 weeks coculture with
HDFs of HUVECs expressing MEK1A compared to control. Scale bar, 100 mm. Western blot shows ERK1/2 phosphorylation in HUVECs expressing MEK1A com-
pared to control.
D: HUVECs transfected with Raf siRNAs or scrambled control oligonucleotides were seeded on confluent HDFs. Tubule count was after 5 days. Results are
average of three independent experiments (6SD). Upper inset shows Western blots for expression of Raf-1 and B-Raf, and lower inset shows ERK1/2 phosphor-
ylation in HUVECs transfected with Raf siRNAs compared to control.experiments, retraction was seen at 8 hr. This increase in MLC2
phosphorylation was reversed by treatment with the pharma-
cological inhibitor of the kinase activity of Rho-kinase Y27632
(Uehata et al., 1997), demonstrating that increased MLC2 phos-
phorylation was the consequence of Rho-kinase activity. A sim-
ilar increase in pMLC stainingwas observed in isolated endothe-
lial cells transfected with Raf siRNAs that had been seeded on
confluent fibroblasts (Figure 6A, right panel). This increase in
pMLC staining was also reversed by treatment with Y27632
(data not shown). These experiments show that inhibition of
ERK1/2 signaling in endothelial cells leads to increased Rho-
kinase activity, suggesting that ERK1/2 act to modulate signal-
ing through Rho-kinase and thereby regulate actomyosin con-
tractility via MLC2 phosphorylation.
Transient inhibition of Rho-kinase and actomyosin
contractility rescues the effects of inhibition
of ERK-MAPK signaling on tube formation in coculture
To test the hypothesis that ERK1/2 act to inhibit Rho-kinase sig-
naling in endothelial cells, we examined whether the effects of
inhibition of ERK-MAPK signaling could be rescued by inhibition
of Rho-kinase. Rho-kinase signaling was blocked using Y27632
(Uehata et al., 1997) or H1152 (Ikenoya et al., 2002) inhibitors. In-
hibitor was added prior to the point of loss of bipolarity andCANCER CELL JANUARY 2006retraction, as determined by time-lapse microscopy. Y27632
treatment reversed the vessel retraction response caused by
treatment with PD184352 (Figure 6B and Movies S5 and S6).
Additionally, Y27632 treatment rescued the loss of bipolarity
of endothelial cells in response to inhibition of ERK1/2 by Raf
siRNAs (Figure 6C) and PD184352 (data not shown). Impor-
tantly, transient inhibition of Rho-kinase during the migratory
phase rescued tube formation in cocultures treated with
PD184352 (Figure 6D) but had no effect on its own (data not
shown). When Rho-kinase alone was inhibited with Y27632 for
a longer period of time (48 hr), there was increased tube forma-
tion (Figure 6D), suggesting that angiogenesis can be negatively
regulated by Rho-kinase signaling. Similarly, treatment with
H1152 led to significant rescue of the effects of inhibiting
ERK-MAPK signaling on tube formation (Figure 6E). Because
we have used two structurally unrelated inhibitors (Uehata
et al., 1997; Ikenoya et al., 2002), these results strongly argue
that ERK-MAPK is acting on Rho-kinase (Ikenoya et al., 2002).
To confirm that these effects result from inhibition of signaling
in the endothelial cells, we used an alternative model, where
HUVECs alone are embedded in thin matrigel containing
VEGF and form loops. PD184352 treatment resulted in cell
rounding and retraction of a subpopulation of HUVECs and re-
duced formation of loops. This reduction in loop formation37
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ure S4), confirming that the rescue by Rho-kinase inhibition
was via a direct effect on endothelial cells (Figure S4). In parallel
with the observation that inhibition of Rho-kinase alone in-
creased tube formation in the coculture system (Figure 6D) inhi-
bition of Rho-kinase alone increased loop formation in the thin
matrigel assay (Figure S4).
To extend the link between ERK-MAPK signaling, Rho-kinase,
MLC2 phosphorylation, and actomyosin contractility, we exam-
ined whether inhibiting actomyosin contractility would over-
come the effects of inhibiting ERK-MAPK signaling on tube for-
mation. Transient treatment of cocultures with blebbistatin, an
inhibitor of myosin II ATPase activity (Straight et al., 2003),
Figure 4. Inhibition of ERK-MAPK signaling in endothelial cells results in loss of
bipolarity, detachment, and cell death
A: HUVECs expressing dominant-negative MEK (MEK1A) or control HUVEC-
EGFP were marked with Oregon green and seeded on confluent HDFs. Bi-
polarity (length/width > 3) was measured after 18 hr. Results are average
of three independent experiments (6SD) using three different pools of
HUVEC-MEK1A or control cells. Scale bar, 50 mm.
B: HUVEC-EGFP were seeded on confluent HDFs, treated with PD184352
(2 mm), and followed by time-lapse microscopy. The percentage of cells
with bipolar morphology was determined after 10 hr treatment, and cell
death was scored from time-lapse movies over 24 hr. Results are average
of three independent experiments (6SD).
C: HUVEC-EGFP were transfected with Raf siRNAs or scrambled control oli-
gonucleotide duplexes and seeded on confluent HDFs. The percentage
of cells with bipolar morphology was determined 48 hr after transfection.
Results are average of three independent experiments (6SD).
D: HUVEC-EGFP were transfected with Raf siRNA or scrambled control oligo-
nucleotide duplexes, seeded on confluent HDFs, and followed by time-
lapse microscopy. Cell death was scored from the movies over 3.5 days
after siRNA transfection and is shown as average of three independent
experiments (6SD). At least 40 cells from each group were followed in each
experiment by time-lapse microscopy. Scale bar, 50 mm.38rescued tube formation in cocultures treated with PD184352
but had no effect on its own (Figure 6F). These findings confirm
that cell retraction and death following inhibition of ERK-MAPK
signaling is the consequence of increased actomyosin contrac-
tility resulting from increased Rho-kinase signaling and MLC2
phosphorylation in endothelial cells.
Abrogation of angiogenesis in vivo through inhibition
of ERK-MAPK signaling is overcome by Rho-kinase
inhibition
These observations in tissue culture suggest that ERK1/2 signal-
ing is required in endothelial cells to oppose the effects of Rho-
kinase signaling on cell morphology during angiogenesis. To
find out if this regulatory pathway operates during tumor angio-
genesis in vivo, we investigated whether treatment with the Rho-
kinase inhibitor Y27632 would rescue the effects of expression
of dominant-negative MEK1 in the vascular compartment of
tumors. Since cells get infected with the MEK1A virus before
the tumors establish in the in vivo model, we administered the
inhibitor early, when tumors had just started appearing, and
continued treatment for 5 days. Tumors were analyzed when
they had reached 0.6–0.7 cm diameter, and blood vessel forma-
tion was studied by staining for CD31 and scoring for blood ves-
sels with open lumens and branching points. Representative
pictures of tumors with MEK1A transduction in the vascular
compartment and control, treated with Y27632 or control vehi-
cle, are shown in Figure 7A. The reduction in angiogenesis in tu-
mors with expression of dominant-negative MEK1 in the vascu-
lar compartment was abrogated when Rho-kinase was inhibited
by treatment with Y27632. There was rescue of the overall
Figure 5. Inhibition of ERK-MAPK signaling results in tube retraction
A: Vessel retraction in response to inhibition of ERK1/2 activation. HUVEC-
EGFP cocultured with HDFs were treated with PD184352 (2 mM) 1 week after
initiation of the coculture. Vessel sprouting was followed by time-lapse mi-
croscopy. Still images are shown at 12 hr intervals from start of inhibitor treat-
ment. Closed arrows show sprouting points in control vessels. Open arrows
indicate retraction points in vessels treated with PD184352. Scale bar, 50 mm.
B: HUVEC-EGFP transfected with Raf siRNA or scrambled control oligonu-
cleotides were seeded on confluent HDFs. Sprouting points on vessels were
counted after 5 days. Results are average of three independent experi-
ments (6SD).CANCER CELL JANUARY 2006
A R T I C L Eamount of vasculature as shown by the increase in the CD31
stained area (Figure 7B), the number of vessels with open lu-
mens (Figure 7C), and total vessel length (Table 1). Although
we found no significant increase in the overall amount of vascu-
lature in response to Rho-kinase inhibition alone in tumors, there
was marked increase in the amount of branching points (Fig-
ure 7D). These results suggest that the inhibition of angiogenesis
resulting from blockade of ERK1/2 signaling in the tumor vascu-
lature is a consequence of aberrant Rho-kinase activity.
To confirm that the reduction in angiogenesis in tumors in re-
sponse to inhibition of ERK-MAPK signaling and the rescue by
Rho-kinase inhibition were via a direct effect on endothelial
cells, we employed an alternative in vivo angiogenesis model
in which endothelial cells are attracted into VEGF-containing
matrigel plugs and form vessels (Eliceiri et al., 1999). Introduc-
tion of retrovirus producer cells into these plugs results in infec-
tion and transgene expression in the vessels (Eliceiri et al., 1999;
Figure S1B). In agreement with the results from the tumormodel,
there was reduced vessel formation in VEGF-matrigel plugs
containing dominant-negative MEK1 retrovirus producers com-
pared to control (Figures 7E and 7F). The reduction in vessel for-
mation was again rescued by treatment with the Rho-kinase
inhibitor Y27632 (Figures 7E and 7F). In similar experiments us-
ing PD184352 treatment rather than expression of dominant-
negative MEK1 to block ERK-MAPK signaling in the VEGF-
matrigel plugs, there was reduced angiogenesis in response
to PD184352 that was rescued by treatment with Y27632
(data not shown).
In agreement with the observation in coculture that inhibition
of ERK1/2 upregulated Rho-kinase-dependent MLC2 phos-
phorylation, there was increased pMLC in tumors treated with
the MEK1 inhibitor PD184352 (Figure 7G). Altogether, these re-
sults demonstrate that the interplay between ERK1/2 and Rho-
kinase signaling that we have identified in the endothelial-fibro-
blast coculture assay operates in vivo.
Discussion
To investigate the role of ERK-MAPK signaling in tumor angio-
genesis, we have selectively inhibited ERK-MAPKby expression
of dominant-negative MEK1 in the vascular compartment of
tumors. A role of ERK-MAPK in tumor angiogenesis has been
suggested (Mukhopadhyay et al., 1998) but not investigated
mechanistically. Inhibition of ERK1/2 signaling in the tumor vas-
culature resulted in vessel reduction, defective vascular mor-
phogenesis, and reduced tumor growth. These results raise
the possibility that drugs to inhibit activation of ERK-MAPK sig-
naling (Sebolt-Leopold and Herrera, 2004) may act both on tu-
mor cells and endothelial cells.
By following tubule formation in endothelial cell-fibroblast co-
cultures by time-lapse microscopy, we demonstrated that inhi-
bition of ERK-MAPK signaling results in upregulation of Rho-
kinase signaling and cell contractility, leading to detachment
of isolated endothelial cells and retraction of sprouting vessels.
Significantly, we observed these effects only under conditions
wheremigration and tubule formation occurs and not with endo-
thelial cells cultured on tissue culture plastic (data not shown).
The interplay between ERK-MAPK andRho-kinase signaling ap-
pears to operate in vivo, as inhibition of ERK-MAPK signaling led
to increasedMLC phosphorylation in tumor vessels, and the de-
fects in vascularization were rescued by inhibition of Rho-kinaseCANCER CELL JANUARY 2006in vivo. Our results suggest that the level of Rho-kinase activa-
tion must be accurately regulated in angiogenic vessels. We hy-
pothesize that reduced actomyosin contractility is necessary to
allow endothelial cell migration and sprouting. This is consistent
with the finding that actomyosin contractility has been shown to
oppose protrusive activity driven by actin assembly (Totsukawa
et al., 2004) (see Figure 8). Furthermore, reduced actomyosin
contractility appears to be necessary to allow cell spreading
and survival during endothelial cell migration, when there are
looser cell-cell and cell-matrix attachments.
The retraction of tubules in response to increased Rho-kinase
activity is consistent with reports that activation of Rho signaling
by the microtubule depolymerizing agent vinblastin results in
collapse of tubes in three-dimensional matrix, and vessel lu-
mens in the chorioallantoic membrane (Bayless and Davis,
2004). The report by Bayless and Davies demonstrates that
aberrant activation of Rho signaling can mediate cytoskeletal
disruption of angiogenic vessels, although it does not address
whether these effects are mediated by Rho-kinase. The retrac-
tion of tubules observed in tissue culture in response to inhibi-
tion of ERK-MAPK signaling and activation of Rho-kinase is con-
sistent with the reduction in vessel length and number of open
lumens seen in tumors. Both in tissue culture and in vivo, these
effects were rescued by inhibiting Rho-kinase. Surprisingly, inhi-
bition of Rho-kinase alone in vivo increased sprouting and
vessel length. These data therefore suggest that inhibition of
Rho-kinase promotes vascular remodeling during angiogenesis.
This suggests that studies using inhibition of Rho-kinase as
a strategy for cancer treatment should include monitoring tumor
vascularization to determine whether Rho-kinase inhibition is
promoting angiogenesis.
We have shown that inhibition of ERK1/2 signaling resulted in
apoptosis of isolated endothelial cells. Although ERK-MAPK sig-
naling has been implicated in the survival of other cell types by
acting on the apoptotic machinery (reviewed in Chang et al.,
2003; Sebolt-Leopold and Herrera, 2004), our data suggest
that endothelial cell death in response to inhibition of ERK1/2 ac-
tivation resulted from changes in cell shape and detachment
from the extracellular matrix as a consequence of increased
Rho-kinase activity during themigratory phase. Our conclusions
are supported by the following: the predominant response to in-
hibition of ERK1/2 signaling during endothelial cell migration
was loss of bipolarity. Following cell rounding, apoptosis took
place approximately 10–12 hr later as revealed by time-lapse
microscopy. Cell rounding and retraction were rescued by
Rho-kinase inhibition but were not inhibited by ZVAD (seeMovie
S7), demonstrating that cell rounding and retraction are not the
result of the induction of apoptosis. It is well established that en-
dothelial cells depend on adhesion to the extracellular matrix to
receive survival signals through the engagement of integrins
(Frisch and Ruoslahti, 1997; Meredith et al., 1993). In addition
to cell adhesion, cell spreading is also necessary for endothelial
cell survival (Chen et al., 1997; Re et al., 1994). As a direct dem-
onstration of the importance of spreading, seeding endothelial
cells on substrates of small surface area leads to apoptosis
even in the presence of integrin engagement (Chen et al.,
1997). Therefore, although cell contractility is necessary for
both cell adhesion and spreading (Balaban et al., 2001), its levels
must be tightly regulated in endothelial cells during angiogene-
sis to support cell survival and allow migration. The finding that
ERK1/2 signaling promotes cell survival through regulating39
A R T I C L EFigure 6. Endothelial cell bipolarity and retraction are rescued by transient inhibition of Rho-kinase and actomyosin contractility in coculture
A: Inhibition of ERK-MAPK signaling leads to elevated Rho-kinase activity in coculture. Left panel: 1 week after initiation, HUVEC-HDF cocultures were treated
with PD184352 (2 mM) for 4 hr and analyzed by immunofluorescence for phosphorylated MLC2 (Ser-19). Where indicated, Y27632 (10 mM) was applied 2 hr
before the cocultures were stained. Scale bar, 50 mm. Right panel: HUVEC-EGFP transfected with scrambled (scr) or Raf siRNAs were seeded on confluent
HDFs. Scale bar, 10 mm.
B: Sprouting of HUVEC-EGFP cocultured with HDFs was followed by time-lapse microscopy 1 week after initiation of coculture. The percentage retraction with
respect to initial tubule length is shown for tubules treated with PD184352 compared to combination with Y27632 after 12 hr treatment. Results are averages of
three independent experiments (6SD). At least six tubules from each group were followed in each experiment by time-lapse microscopy.
C: HUVECs transfected with Raf siRNA or scrambled control oligonucleotides were seeded on confluent HDFs. The percentage of cells with bipolar morphol-
ogy (length/width > 3) was determined 48 hr after transfection. Results are averages of three independent experiments (6SD).
D: Inhibition of Rho-kinase by Y27632 leads to rescue of tube formation when ERK1/2 activation is inhibited. Seven days after initiation, HUVEC-HDF cocultures
were treated with PD184352 or Y27632 for 48 hr. In combination, Y27632 treatment was for 8 hr on day 1 and day 2 of 48 hr PD184352 treatment. After treat-
ment, media containing inhibitors were removed and replaced with fresh tissue culture media. Tube formation was assessed by CD31 staining after a further 5
days. Tubule count is represented as 6SD (n = 9 microscopic fields at 34 magnification from triplicate wells).40 CANCER CELL JANUARY 2006
A R T I C L ERho-kinase activity does not exclude the possibility that ERK-
MAPK regulates bona fide survival signals during endothelial
cell proliferation, or to protect cells from receptor-mediated
cell death (Alavi et al., 2003).
While inhibition of ERK-MAPK signaling had marked effects
during the migratory phase, there was a much smaller effect in
established tubes. This observation is in agreement with the
findings of Eliceiri and coworkers, who showed that only the for-
mation of new blood vessels in response to bFGF stimulation
was compromisedwhen ERK-MAPKwas inhibited in the chorio-
allantoic membrane (Eliceiri et al., 1998). Therefore, there may
be lower MAPK-ERK activity in established tubes in coculture.
Alternatively, MAPK signaling may be uncoupled from Rho-
kinase signaling in established tubes. In agreement with the pro-
posed interplay between ERK1/2 and Rho-kinase signaling, we
found elevated levels of phosphorylated MLC2 in established
tubules compared to isolated endothelial cells and sprouting tu-
bules, indicative of higher Rho-kinase activity. We would argue
based on our results and those of others that during angiogen-
esis it is necessary to downregulate Rho-kinase to promote cell
spreading and cell migration, whereas to form stable vessels up-
regulated Rho-kinase activity may be necessary to inhibit the
generation of cell protrusions (Arthur and Burridge, 2001), main-
tain tight junctions (Wojciak-Stothard and Ridley, 2002), and
stabilize vessels. This notion is supported by the finding that
Rho signaling promotes the organization of confluent layers of
endothelial cells into cords and the assembly of endothelial cells
into vessels in vivo (Hoang et al., 2004). In mature vessels, sur-
vival factors and mechanical support from established cell-cell
contacts and stable cell-matrix adhesions (Dejana, 2004) may
protect the cells from the effects of elevated actomyosin con-
tractility.
In summary, we have demonstrated that inhibiting MAPK-
ERK in the vasculature of tumors inhibits angiogenesis and re-
duces tumor growth and revealed a role of ERK-MAPK signaling
during angiogenesis, namely its role in downregulating Rho-
kinase activity to allow endothelial cell spreading, survival, and
sprouting of vessels. This mechanism has been elucidated by
the use of an organotypic angiogenesis assay and confirmed
by in vivo approaches. We propose that ERK-MAPK signaling
plays a key role in controlling vascular morphogenesis through
opposing the effects of Rho-kinase activation. As tumor vascu-
larization may result from different mechanisms in different tu-
mor types, detailed studies of human tumor material will be
needed to determine in which tumor systems the vasculature
can be compromised by targeting ERK-MAPK signaling and
the induction of Rho-kinase-mediated retraction and cell death.
Phospho-MLC2 and phospho-ERK may be useful markers in
such studies. Potentially, some antiangiogenic agents that act
on tumor blood vessels may act through downregulation of
ERK-MAPK signaling and consequent upregulation of Rho-
kinase signaling. Interestingly, combretastatin A-4-phosphate,
a tumor vascular targeting agent, seems towork by upregulationCANCER CELL JANUARY 2006of Rho-kinase andMLC activity, and its effects are abrogated by
ERK1/2 activation (Kanthou and Tozer, 2002).
Experimental procedures
Cells, retroviral infection, and electroporation
Angiokit-validated HDFs and HUVECs were obtained from TCS CellWorks
(Buckingham, UK) and cultured in DMEM 10% FCS and Large Vessel Endo-
thelial Medium (TCSCellWorks), respectively. HUVEC-EGFPwere generated
by viral infection of HUVECs with an EGFP pBabe-puro (Morgenstern and
Land, 1990) amphotropic, replication-defective retrovirus. EGFP-expressing
cells were sorted by FACS. HUVEC-MEK1A were generated by infection
with a MEK1A pBabe-puro amphotropic retrovirus, followed by selection in
0.5 mg/ml puromycin. All HUVECs were used up to passage 6, and their
tube-forming ability was assessed in a 2 week coculture assay with HDFs
(see below). Plasmid DNA and siRNAs were introduced into HUVECs by
electroporation using the HUVEC (Vs.2) Nucleofector Kit (Amaxa GmbH,
Germany).
Constructs and recombinant retroviruses
pEXVMEK1A (dominant-negativeMEK1with Ser-217 substitution to alanine)
and retroviral vectors pBabe-puro MEK1A and MEK1EE (active MEK1 with
Ser-217 and Ser-221 substitution to glutamic acid) have been previously de-
scribed (Cowley et al., 1994). High-titer retrovirus producer lines were gener-
ated as previously described (Mavria and Porter, 2001).
Antibodies, siRNAs, and inhibitors
Antibody against phospho-MLC2 (Ser-19) was from Cell Signaling Technol-
ogy, CD31 and Raf-1 were from BD Biosciences, B-Raf was from Santa Cruz
Biotechnology, and phospho-ERK1/2 was from Sigma. siRNAs forRaf-1 and
B-Raf (Karasarides et al., 2004) were from Qiagen. PD184352 (Sebolt-
Leopold et al., 1999), H1152 (Ikenoya et al., 2002), and blebbistatin (Straight
et al., 2003) were from Calbiochem, and Y-27632 was from Tocris (South-
ampton, UK).
Immunofluorescence and time-lapse microscopy
For immunofluorescence, fixation was in 3.7% paraformaldehyde, and per-
meabilization was in 0.1% Triton X-100. Apoptotic cells were detected using
the DeadEnd Fluorometric TUNEL System (Promega). Cells were imaged by
confocal microscopy. Multisite microscopy was performed in a humidified,
CO2-equilibrated chamber using a Diaphot inverted microscope (Nikon,
Kingston upon Thames, UK) equipped with a motorized stage (Prior Scien-
tific, Oxford, UK) controlled by Simple PCI software (Compix, Cranberry
Township, PA).
Coculture angiogenesis assays
Cocultures of HUVECs with HDFs (TCS Angiokit) were purchased from TCS
CellWorks, Buckingham, UK. Pharmacological inhibitors were applied 7 days
after initiation of the coculture with no change of media for 48 hr prior to ap-
plication. Tube formation was assessed by immunohistochemistry using
a mouse anti-human CD31 Tubule Staining Kit (TCS CellWorks). Anti-
human CD31 was applied at 1:400 dilution and alkaline phosphatase-
conjugated secondary at 1:500. The substrate was applied for 15 min and
washed, and pictures of the cocultures were taken after 4–5 hr. Coculture as-
says of HUVEC-MEK1A and HUVEC-EGFP with HDFs were set up as previ-
ously described (Bishop et al., 1999). Short-term assays following electropo-
ration of HUVECswere set up by seeding HUVECs onHDFs that had reached
confluency after 7 days in culture. HUVECs marked with Oregon green
(Molecular Probes) were cultured alone overnight before seeding on HDFs.E: Inhibition of Rho-kinase by H1152 leads to rescue of tube formation when ERK1/2 activation is inhibited. Seven days after initiation, HUVEC-HDF cocultures
were treated with PD184352 or H1152 (5 mM) for 24 hr. In combination with PD184352, H1152 was added 12 hr after PD184352. After treatment, media contain-
ing the inhibitors were removed and replaced with fresh tissue culture media. Tube formation was assessed by CD31 staining after a further 5 days. Tubule
count is represented as 6SD (n = 9 microscopic fields at 34 magnification from triplicate wells).
F: Inhibition of actomyosin contractility by blebbistatin leads to rescue of tube formation when ERK1/2 activation is inhibited. Cocultures were treated with
PD184352 or blebbistatin (5 mM; Wilkinson et al., 2005) as in E. In combination, blebbistatin was added 12 hr after PD184352. Tubule count is represented as
in E.41
A R T I C L EFigure 7. The block to angiogenesis in vivo resulting from inhibition of ERK-
MAPK signaling is overcome by Rho-kinase inhibition
A–D: Inhibition of Rho-kinase leads to rescue of angiogenesis in tumors when
ERK-MAPK signaling is inhibited in the tumor vasculature. BE tumors with
MEK1A (dominant-negative MEK1) or control (EGFP) retroviral transduction
in the vascular compartment were set up as described in Experimental Pro-
cedures. Y27632 was administered for 5 days after tumors appeared. Tumors
were analyzed when they reached approximately 0.6 cm diameter; cryo-
sections were examined by immunofluorescence for CD31 expression. A:
Typical sections are shown of tumors with MEK1A or control transduction
treated with Y27632 or vehicle. Scale bar, 100 mm. The fractional area cov-
ered by CD31+ features (B), the number of vessels with open lumens (C), and
the number of branching points (D) are represented as mean6 SD (n = 4 tu-
mors). Counts for each tumor were from eight sections, representing four dif-
ferent levels. For each section, the microscopic field (320) showing the
greatest level of CD31 staining was counted.42In vivo angiogenesis assays, inhibitor treatment,
and vessel measurement
All in vivo experimentation was performed according to United Kingdom
Home Office Regulations and the United Kingdom CCCR guidelines. For tu-
mor growth assays, BE or MDA-MB-361 tumor cells (1.5 3 106) were mixed
with irradiated (20 Gy) ecotropic virus producers at 1:10 ratio and inoculated
subcutaneously into the right flank of 5- to 6-week-old male MF1 nu/nu mice
(Harlan). Tumor volumes were calculated according to the formula V(mm3) =
(L3W2)3 1/2 (Ovejera et al., 1978). Where tumors reached 1500 mm3 in the
control group, animals were removed from the study according to UK Home
Office guidelines. Treatment with Y27632 was intraperitoneal at 50 mg/kg
body weight (Erik Sahai, personal communication), twice daily starting at
10 days after inoculation of tumor cells. Treatment with PD184352 was intra-
peritoneal at 200mg/kg bodyweight (Sebolt-Leopold et al., 1999), daily start-
ing after the tumors appeared.Matrigel angiogenesis assayswere carried out
essentially as previously described (Eliceiri et al., 1999) using growth factor-
depleted Matrigel (Becton Dickinson) supplemented with VEGF (400 ng/ml).
The plugs were excised 6 days after inoculation.
Cryosections (10 mm) for immunofluorescence were cut from dissected tu-
mors and matrigel plugs frozen in OCT compound (Sakura) and analyzed by
confocal microscopy using a 320 objective. Automated analysis of the pro-
portion of the image represented byCD31-positive cells andmeasurement of
vessel length were performed using the Scion Image software. DAPI staining
E and F: Inhibition of ERK-MAPK signaling blocks angiogenesis in a VEGF-
driven in vivo model and is overcome by inhibition of Rho-kinase. VEGF-ma-
trigel plugs containing MEK1A or EGFP retrovirus producers were set up as
described in Experimental Procedures. Y27632 was administered for 3 days
starting 3 days after inoculation. Matrigel plugs were analyzed at the end
of treatment; cryosections were examined by immunofluorescence for
CD31 expression. E: Sections typical of the difference in vascular density be-
tween plugs with MEK1A virus in the presence or absence of Y27632 are
shown. Scale bar, 100 mm. F: The fractional area covered by CD31+ features
is represented as mean 6 SD (n = 4 tumors). Counts for each tumor were
from sections from three different levels. For each section, the microscopic
field (320) showing the greatest level of CD31 staining was counted.
G: Inhibition of ERK-MAPK signaling leads to elevated levels of phosphory-
lated MLC2 in tumors. BE tumors were established in nude mice, and
PD184352 was administered for 4 days after the tumors appeared. Tumors
were analyzed at the end of treatment; cryosections were examined by im-
munofluorescence for expression of CD31 and phosphorylated MLC2 (Ser-
19). Scale bar, 50 mm.
Figure 8. Model for interaction between ERK-MAPK signaling and Rho-ki-
nase signaling during angiogenesisCANCER CELL JANUARY 2006
A R T I C L Ewas used to confirm the lack of nucleated cells in vessels when scoring open
lumens, and to distinguish the tumor area from the surrounding stroma
(looser cell appearance). Vessels within the surrounding stroma were ex-
cluded from the analysis, as were arterial vessels identified by their autofluo-
rescence in the green channel.
Supplemental data
The Supplemental Data include four supplemental figures, two supplemental
tables, and seven movies and can be found with this article online at http://
www.cancercell.org/cgi/content/full/9/1/33/DC1/.
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